ATAI LIFE SCIENCES NV (9VC.DE) Stock Fundamental Analysis
Europe - FRA:9VC - NL0015000DX5 - Common Stock
3.65 EUR
-0.05 (-1.43%)
Overall 9VC gets a fundamental rating of 3 out of 10. We evaluated 9VC against 54 industry peers in the Pharmaceuticals industry. 9VC has a great financial health rating, but its profitability evaluates not so good. 9VC is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
9VC had negative earnings in the past year.
In the past year 9VC has reported a negative cash flow from operations.
In the past 5 years 9VC always reported negative net income.
9VC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
9VC has a worse Return On Assets (-78.89%) than 85.19% of its industry peers.
9VC has a Return On Equity of -103.85%. This is in the lower half of the industry: 9VC underperforms 79.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -78.89% | ||
| ROE | -103.85% | ||
| ROIC | N/A |
ROA(3y)-52.42%
ROA(5y)-70.02%
ROE(3y)-67.79%
ROE(5y)-86.99%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
9VC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
9VC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, 9VC has more shares outstanding
9VC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for 9VC is higher compared to a year ago.
2.2 Solvency
9VC has an Altman-Z score of 6.31. This indicates that 9VC is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.31, 9VC belongs to the top of the industry, outperforming 85.19% of the companies in the same industry.
There is no outstanding debt for 9VC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.31 |
ROIC/WACCN/A
WACC7.52%
2.3 Liquidity
9VC has a Current Ratio of 4.02. This indicates that 9VC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.02, 9VC belongs to the top of the industry, outperforming 92.59% of the companies in the same industry.
9VC has a Quick Ratio of 4.02. This indicates that 9VC is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of 9VC (4.02) is better than 92.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.02 | ||
| Quick Ratio | 4.02 |
3. Growth
3.1 Past
9VC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -72.50%.
Looking at the last year, 9VC shows a decrease in Revenue. The Revenue has decreased by -1.91% in the last year.
9VC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -75.28% yearly.
EPS 1Y (TTM)-72.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.11%
Revenue 1Y (TTM)-1.91%
Revenue growth 3Y-75.28%
Revenue growth 5YN/A
Sales Q2Q%163.37%
3.2 Future
Based on estimates for the next years, 9VC will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.19% on average per year.
The Revenue is expected to grow by 236.62% on average over the next years. This is a very strong growth
EPS Next Y45.22%
EPS Next 2Y23.88%
EPS Next 3Y13.75%
EPS Next 5Y14.19%
Revenue Next Year355.42%
Revenue Next 2Y-36.68%
Revenue Next 3Y18.97%
Revenue Next 5Y236.62%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
9VC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 9VC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
9VC's earnings are expected to grow with 13.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.88%
EPS Next 3Y13.75%
5. Dividend
5.1 Amount
No dividends for 9VC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:9VC (11/7/2025, 7:00:00 PM)
3.65
-0.05 (-1.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners13.93%
Inst Owner ChangeN/A
Ins Owners2.66%
Ins Owner ChangeN/A
Market Cap861.29M
Revenue(TTM)308.00K
Net Income(TTM)-149.27M
Analysts83.53
Price Target10.65 (191.78%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.25%
Min EPS beat(2)-17.64%
Max EPS beat(2)17.15%
EPS beat(4)1
Avg EPS beat(4)-15.72%
Min EPS beat(4)-62.27%
Max EPS beat(4)17.15%
EPS beat(8)4
Avg EPS beat(8)10%
EPS beat(12)7
Avg EPS beat(12)5.89%
EPS beat(16)9
Avg EPS beat(16)-5.32%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.16%
PT rev (3m)16.5%
EPS NQ rev (1m)-5.73%
EPS NQ rev (3m)-11.73%
EPS NY rev (1m)-2.33%
EPS NY rev (3m)-5.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)3.54%
Revenue NY rev (3m)59.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3232.92 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.93 | ||
| P/tB | 7.1 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.6
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0
BVpS0.53
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -78.89% | ||
| ROE | -103.85% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-52.42%
ROA(5y)-70.02%
ROE(3y)-67.79%
ROE(5y)-86.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 830.23% | ||
| Cap/Sales | 2024.35% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.02 | ||
| Quick Ratio | 4.02 | ||
| Altman-Z | 6.31 |
F-Score2
WACC7.52%
ROIC/WACCN/A
Cap/Depr(3y)268.35%
Cap/Depr(5y)673.01%
Cap/Sales(3y)220.74%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-72.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.11%
EPS Next Y45.22%
EPS Next 2Y23.88%
EPS Next 3Y13.75%
EPS Next 5Y14.19%
Revenue 1Y (TTM)-1.91%
Revenue growth 3Y-75.28%
Revenue growth 5YN/A
Sales Q2Q%163.37%
Revenue Next Year355.42%
Revenue Next 2Y-36.68%
Revenue Next 3Y18.97%
Revenue Next 5Y236.62%
EBIT growth 1Y18.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.75%
EBIT Next 3Y-16.28%
EBIT Next 5Y-3.12%
FCF growth 1Y21.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.11%
OCF growth 3YN/A
OCF growth 5YN/A
ATAI LIFE SCIENCES NV / 9VC.DE FAQ
What is the ChartMill fundamental rating of ATAI LIFE SCIENCES NV (9VC.DE) stock?
ChartMill assigns a fundamental rating of 3 / 10 to 9VC.DE.
What is the valuation status of ATAI LIFE SCIENCES NV (9VC.DE) stock?
ChartMill assigns a valuation rating of 0 / 10 to ATAI LIFE SCIENCES NV (9VC.DE). This can be considered as Overvalued.
What is the profitability of 9VC stock?
ATAI LIFE SCIENCES NV (9VC.DE) has a profitability rating of 0 / 10.
Can you provide the expected EPS growth for 9VC stock?
The Earnings per Share (EPS) of ATAI LIFE SCIENCES NV (9VC.DE) is expected to grow by 45.22% in the next year.